- Home
- CVBF vs GLPG Comparison
CVBF vs GLPG Comparison
Compare CVBF & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CVBF | GLPG |
|---|---|---|
| Founded | 1974 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 704 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | CVBF | GLPG |
|---|---|---|
| Price | $18.88 | $32.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $24.17 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 1.1M | 87.8K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | ★ 5.56 | N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.55 | N/A |
| Revenue Next Year | $15.13 | N/A |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.01 | $22.59 |
| 52 Week High | $21.48 | $37.78 |
Technical Indicators
Market Signals| Indicator | CVBF | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 41.98 |
| Support Level | $18.16 | $32.07 |
| Resistance Level | $19.56 | $33.56 |
| Average True Range (ATR) | 0.55 | 0.80 |
| MACD | -0.16 | -0.14 |
| Stochastic Oscillator | 16.97 | 9.50 |
Price Performance
Historical ComparisonAbout CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.